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This study aimed to investigate the adjuvant effect of recombinant attenu-
ated Salmonella expressing cholera toxin B subunit (CTB) and Escherichia coli 
heat-labile enterotoxin B subunit (LTB) for the P-fimbriae subunit-based vaccine 
of avian pathogenic E. coli (APEC) in a murine model. The PapA-specific sIgA 
and IgG responses were significantly enhanced after immunisation with the Sal-
monella-PapA vaccine in the presence of CTB or LTB. The group immunised 
with the Salmonella-LTB strain promoted Th1-type immunity, whereas that im-
munised with the Salmonella-CTB strain produced Th2-type immunity. We con-
cluded that both Salmonella-CTB and -LTB strains can enhance the immune re-
sponse to PapA, and that the LTB strain may be a more effective adjuvant for 
APEC vaccination, which requires higher Th1-type immunity for protection. 
Thus, our findings provide evidence that immunisation with an adjuvant, LTB, is 
one of the strategies of developing effective vaccines against P-fimbriated APEC. 
Key words: APEC, Salmonella vaccine delivery, CTB, LTB, immune re-
sponse 
Avian pathogenic Escherichia coli (APEC) belongs to the extraintestinal 
pathogenic group of E. coli. These bacteria cause airsacculitis, omphalitis, peri-
tonitis, salpingitis, synovitis, and coli septicaemia in poultry (Pourbakhsh et al., 
1997; Dho-Moulin and Fairbrother, 1999; Vandemaele et al., 2002; Ewers et al., 
2004). Several virulence factors, including P-fimbriae, have been associated with 
APEC which, however, do not occur universally (Dziva and Stevens, 2008; Ewers 
et al., 2009; Tóth et al., 2012). Among them, the major subunit of P-fimbriae, 
PapA, appears to be a suitable candidate as a vaccine target against APEC (Oh et 
al., 2011). 
Oral vaccines can promote mucosal immune responses, as well as provide 
safe, readily acceptable methods for inducing systemic immune responses (Ogra 
                                                 
*Corresponding author; E-mail: johnhlee@jbnu.ac.kr; Phone: 0082 (63) 270-2553;  
Fax: 0082 (63) 270-3780 
294 OH et al. 
Acta Veterinaria Hungarica 62, 2014 
et al., 2001; Zhao et al., 2006). Mucosal immune responses are important for pro-
tecting mucosal surfaces against invasion by microbes, blocking the uptake of 
ungraded antigens, and preventing the development of potentially injurious im-
mune responses to these antigens (Holmgren and Czerkinsky, 2005). However, 
mucosal immunisations are frequently ineffective due to weak antigen uptake 
from mucosal surfaces, and a large dose of antigen is required for induction of 
immune responses against specific antigens (Ogra et al., 2001). Adjuvants are 
generally added to the antigens to promote higher immune responses (Holmgren 
et al., 1992). 
A number of products of bacterial origin have been tested as mucosal ad-
juvants, including bacterial toxins such as cholera toxin (CT) and E. coli heat-
labile enterotoxin (LT) (Freytag and Clements, 1999; Fingerut et al., 2006). Both 
CT and LT are composed of one enzymatically active A unit and five B units 
that bind to ganglioside GM1 expressed on the eukaryotic cell surface. The non-
toxic B subunits of CT (CTB) and LT (LTB) have also been used as adjuvants, 
as they increase antigen uptake from mucosal surfaces, thus increasing the hu-
moral and cellular immune responses (Holmgren et al., 1993; Yamamoto et al., 
1997; McCluskie et al., 2001). LTB and CTB proteins have been successfully 
expressed in different expression systems such as Mycobacterium bovis and Lac-
tobacillus or Bacillus brevis (Slos et al., 1998; Hayward et al., 1999; Goto et al., 
2000). Recently, live attenuated Salmonella bacteria were employed for delivery 
of antigens for mucosal vaccination (Branger et al., 2007, Oh et al., 2011). Sal-
monella bacteria as a carrier target the mucosal-associated lymphoid tissues in 
the gut and thereby improve the possibility of stimulating mucosal immunity, 
which may be important for providing protection against some infectious agents 
(Sirard et al., 1999). A balanced-lethal host-vector system based on the essential 
bacterial aspartate β-semialdehyde dehydrogenase (asd) gene has been used to 
specify recombinant antigens from the Asd+ plasmids pYA3493 and pYA3560 
(Nakayama et al., 1998; Kang et al., 2002). 
In this study, we constructed recombinant attenuated S. Typhimurium 
strains that express PapA, CTB and LTB. We used mice to evaluate whether oral 
vaccination with a live attenuated S. Typhimurium strain expressing PapA in-
duced stronger immune responses when inoculated with recombinant CTB and 
LTB or when inoculated with another S. Typhimurium strain expressing CTB or 
LTB as an adjuvant. We also examined the effect of synergy between these adju-
vant strains. 
 
Materials and methods 
Bacterial strains, plasmids and growth conditions 
The hisG Δcrp-28 ΔasdA16 attenuated S. Typhimurium χ8501 (Gulig and 
Curtiss, 1987) was used for the delivery of antigen proteins. Plasmids pYA3493 
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and pYA3560 were described previously (Oh et al., 2011). All strains were 
grown at 37 °C in Luria-Bertani (LB) media (Difco, Sparks, MD, USA) with or 
without antibiotics. Diaminopimelic acid (DAP) (Sigma, St Louis, MO, USA) 
was added for the growth of Asd– strains (Nakayama et al., 1998). Phosphate-
buffered saline containing 0.01% gelatine was used for the suspension of the 
vaccine strains. 
Construction of PapA vaccine and adjuvants 
For construction of PapA, LTB, and CTB strains, each gene was obtained 
by polymerase chain reaction using a pair of primers:  
PapA (F, 5'CCGCGAATTCGCTCCAACTATTCCACAG3'; R, 5'CCCGCG 
TCGACTTACTGGTAACTTAAAT') (GenBank accession no. AF237478.1), LTB 
(F, 5’CCGCGAATTCGCTCCCCAGTCTATTACAG3’; R, 5’CCGCAAGCT 
TCTAGTTTTCCATACTGATTG3’) (GenBank accession no. AB011677.1), and 
CTB (F, 5’GAATTCGCTCCCATGGCTTTCGCTAC3’; R, 5’AATCTTACATGT 
TTGGGCAA3’) (GenBank accession no. JQ683136.1). These primers were de-
signed using the DNASTAR Lasergene 5.07/5.52 programme (DNASTAR Inc., 
USA). The size of PCR products for the PapA, LTB and CTB genes were 486, 327 
and 408 base pairs, respectively. The primers used for PCR amplification of the 
PapA gene carried the restriction digestion sites for EcoRI-SalI, and primers for 
CTB and LTB carried EcoRI and HindIII sites. The asd+ pYA3493 and pYA3560 
were used as backbone plasmids. The amplified PCR products of PapA and CTB 
were cloned in plasmid pYA3493, and the LTB product was cloned in pYA3560. 
The presence of inserts in these plasmids was confirmed by restriction digestion 
with respective enzymes. These cloned plasmids were individually introduced 
into asd– χ6212, to obtain the balanced-lethal E. coli constructs. The purified 
plasmids obtained from the balanced-lethal E. coli constructs were then electro-
porated into the attenuated S. Typhimurium strain χ8501, and resulted in strains 
JOL713 (PapA), JOL757 (CTB) and JOL 758 (LTB), respectively. Selection for 
transformants was achieved by growth on LB agar plates without DAP supple-
mentation. Only clones containing the recombinant plasmids were able to grow 
under these conditions. 
Western blot analyses 
Secreted antigen proteins from recombinant strains were obtained from 
cell-free culture supernatants by the TCA-precipitation process (Oh et al., 2011). 
Attenuated Salmonella containing the pYA3493 vector was used as control. Pro-
tein samples were separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to 0.2 µm microporous polyvi-
nylidene fluoride membranes (Millipore, Bedford, MA, USA) for Western blot 
analysis. Membranes were probed with polyclonal rabbit antisera (1:500 dilu-
296 OH et al. 
Acta Veterinaria Hungarica 62, 2014 
tion) specific for each antigen. The secondary antibody, the goat anti-rabbit HRP 
conjugated antibody (Southern Biotech, USA) was used for detection of recom-
binant protein at dilution of 1:5000. 
Immunisation and collection of samples 
Groups of 6-week-old female BALB/c mice were immunised with Salmo-
nella-PapA vaccine, JOL 713 alone or in combination with the LTB, JOL 758 
and/or CTB, JOL 757 strains (Table 1). There were 10 mice in each group. All 
the mice were maintained at an antibiotic-free autoclaved feed and water. A total 
of 20 µl containing 2 × 109 colony-forming units of bacterial cells were orally 
administered. Sera were obtained by retro-orbital puncture in heparinised capil-
lary tubes and centrifuged at 4,000 × g for 5 min. Vaginal samples were collected 
by washing the vaginal cavity with 100 µl of PBS. All samples were collected 
over a 14-week period at 2-week intervals and were stored at –20 °C until as-
sessed by ELISA. 
Table 1 
Experimental groups of mice in this study 
Group Bacterial strain used 
A JOL713 (PapA ) 
B JOL713 + JOL757 (CTB) 
C JOL713 + JOL758 (LTB) 
D JOL713 + JOL757 + JOL758 
 
Determination of antibody titres 
PapA-specific antibodies in the serum and vaginal samples were detected 
by enzyme-linked immunosorbent assay (ELISA). Polystyrene 96-well flat-
bottom microtitre plates were coated with 1 μg of purified PapA per well and 
blocked with PBS containing 3% skim milk at 4 °C overnight. Vaginal secretions 
and sera were diluted 1:4 and 1:100, respectively. A 100-µl volume of diluted 
sample was added to individual wells in duplicate and incubated for 1.5–2 h at 
37 °C. Plates were treated with horseradish peroxidase-conjugated goat anti-
mouse IgG, IgG1 or IgG2a (Southern Biotechnology Inc., Birmingham, AL, 
USA) for sera and IgA for vaginal secretions. The reactions were visualised with 
o-phenylenediamine (Sigma) and stopped with H2SO4. The absorbance in each 
well was measured using an automated ELISA spectrophotometer (TECAN, 
Salzburg, Austria) at a wavelength of 492 nm. The concentrations of antibodies 
were determined by comparing results of two concentrations of the standard 
mouse IgG (Southern Biotech). 
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Statistical analysis 
Independent-samples t-test was used to determine significant differences 
in antibody titres between immunised and control groups and significant differ-
ences in antibody titres of IgG2a and IgG1 in immunised groups. Statistical re-
sults were considered significant when P values were < 0.05. All statistical 
analyses were carried out with the SPSS 16.0 programme (SPSS Inc.). 
 
 
Results 
Expression of PapA, CTB and LTB in attenuated S. Typhimurium 
The papA, CTB and LTB genes were cloned into expression vector as de-
scribed in the Materials and methods, and the expression of each protein was de-
termined by conducting Western blot analysis with specific antibodies against 
each of the proteins. The strains produced the PapA, LTB and CTB at approxi-
mate molecular weights of 20.3 kDa, 11 kDa and 13.6 kDa, respectively, and 
large amounts of these proteins were detected in the culture supernatant (Fig. 1). 
Little or no protein was detected in the control supernatant. 
 
Fig. 1. Protein expression as measured by Western blot analysis. Each protein is indicated by an ar-
row. Molecular sizes in kilodaltons are PapA, 20.3; LTB, 11; CTB, 13.6. Lanes: 1, control contain-
ing pYA3493 only; 2, PapA, LTB and CTB strains 
Serum anti-PapA IgG responses 
The induction of plasma IgG responses against the purified PapA antigen 
was monitored in the weeks after vaccination. At week 1, groups immunised in 
conjunction with CTB and LTB produced similar PapA-specific IgG antibodies 
as the non-adjuvant group. At week 2, groups immunised in conjunction with 
← PapA 
 1 2 
← LTB 
← CTB 
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CTB and LTB (Group B and Group C, respectively) produced about 2.4 times 
higher levels of PapA-specific IgG antibodies compared to the non-adjuvant 
group (Group A) (Fig. 2A). However, the group immunised in conjunction with 
both adjuvants (Group D) produced similar PapA-specific IgG antibodies as the 
non-adjuvant group. After week 10, the antibody titres in Group B and Group C 
continued to increase, but a slight decrease was observed in Group A and Group 
D, immunized with both CTB and LTB. Over the course of the experimental pe-
riod, antibody titres were observed in the order Group C > Group B > Group A > 
Group D. 
 
Fig. 2. Anti-PapA antibody titres in serum (A) and vaginal samples (B) during the observed  
periods. Mice were immunised as shown in Table 1. Group A, immunisation with PapA alone; 
Group B, immunisation with PapA combined with CTB; Group C, immunisation with PapA  
combined with LTB; Group D, immunisation with PapA combined with CTB and LTB.  
Data are the mean of all mice in each group; error bars show SD. Asterisks indicate a significant 
difference between the values of Groups B, C and D mice (*P < 0.05) and those of Group A mice 
Mucosal anti-PapA sIgA responses 
In order to evaluate the mucosal immune responses induced after vaccina-
tion, the PapA protein specific sIgA titres were estimated from the vaginal wash 
samples. The sIgA titres in all adjuvant groups (Groups B, C and D) were higher 
than those in the non-adjuvant group, Group A (Fig. 2B). Overall, Group B with 
CTB generated the highest titre among the groups. At week 4, the antibody titre 
in each of Groups A, C and D reached its peak. Thereafter, titres in Group A de-
clined rapidly, but the decrease was slow in Groups C and D. The IgA titres in 
Group B continued to increase and were around 4 times higher than in other 
groups. These data indicate that the inclusion of CTB adjuvant with the vaccine 
candidate enhances the production of mucosal immune responses. 
Weeks post inoculation 
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PapA-specific IgG1 and IgG2a subtypes 
To further evaluate the nature of immunity following immunisation, we 
determined the levels of IgG isotype subclasses IgG2a and IgG1 at week 12 after 
immunisation. Different trends were observed depending on the types of adju-
vants used (Fig. 3). Group B with CTB produced about 4 times higher level of 
IgG1 isotype compared to the other groups; however, Group C with LTB pro-
duced more IgG2a isotype than either Group B or Group D, and in Group D a 
higher level of IgG2a isotype production was induced than in Group A. The 
IgG2a/IgG1 ratios in Groups A, B, C and D were approximately 2.0, 0.5, 9.1 and 
5.8, respectively (P < 0.05). 
 
Fig. 3. PapA-specific IgG1 and IgG2a responses. Immunisation groups were Group A, immunisa-
tion with PapA; Group B, immunisation with PapA combined with CTB; Group C, immunisation 
with PapA combined with LTB; Group D, immunisation with PapA combined with CTB and LTB. 
Data are the mean of all mice in each group; error bars show SD. Asterisks indicate a significant 
difference between the values of Groups B, C and D mice (*P < 0.05) and those of Group A mice 
 
 
Discussion 
The induction of immune responses following mucosal immunisation usu-
ally depends on the co-administration of appropriate adjuvants (Zhang et al., 
2008). Adjuvants are substances that, when co-administered with antigen, can 
modulate antigen-specific immune responses. A few adjuvants have been exam-
ined for viral infections such as Newcastle disease in chickens (Zhang et al., 
2007). However, few studies of adjuvants have yet been performed for bacterial 
infections of chickens. 
The mucosal adjuvants most commonly used in animal models are cholera 
toxin (CT), E. coli heat-labile enterotoxin (LT) and their derivatives (Freytag and 
Clements, 2005). Mucosal adjuvants such as LT and CT are highly effective but 
are generally considered to be potent enterotoxins. Efforts to develop less toxic 
versions that would be safe for use have focused on the use of the non-toxic B 
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subunit, which lacks enzymatic activity (Yamamoto et al., 1997; McCluskie et al., 
2001). In some studies, mucosal co-immunisation with CTB or LTB has been shown 
to enhance the systemic and mucosal immune responses to co-administered anti-
gens (Isaka et al., 1999; de Haan et al., 2001). Similarly, our study showed that 
PapA-specific serum IgG and mucosal IgA titres increased significantly when 
mice were administered Salmonella-PapA vaccine in the presence of Salmonella-
LTB or -CTB. Rapid declines in immune responses during the entire experimen-
tal period were observed in mice immunised without adjuvant. Particularly, 
groups with LTB had much higher induction of serum IgG titres compared to 
other groups in this study. Previous reports have suggested that LTB is markedly 
enhanced in the mucosal and systemic immune response to various foreign anti-
gens (Verweij et al., 1998; Fingerut et al., 2006). LTB, which has non-toxic ac-
tivity, is responsible for binding to the monosialotetrahexosylganglioside (GM1) 
ganglioside-receptor of target cells to take up whole toxin units within the cell. 
LTB acts to modulate cell-mediated responses (Th1) to humoral responses (Th2) 
(Simmons et al., 2001). LTB enhances the uptake of co-administered proteins 
(Freytag and Clements, 2005) and both mucosal and cellular immune responses 
(Fingerut et al., 2006). In addition, LTB is highly pH- and protease-resistant; it 
resists degradation during transit through the gastrointestinal system (Ruddock et 
al., 1995), making LTB an effective adjuvant for mucosal immunisation. 
Th1-type responses in mice are generally associated with enhanced levels 
of IgG2a antibodies, which are thought to have superior neutralising capabilities, 
and cytotoxic T lymphocyte (CTL), which are desirable for protection against in-
tracellular bacterial pathogens (Strindelius et al., 2004). Th2-type immune re-
sponses provide B-cell antibody production and promote class switching to IgG1 
(McCluskie et al., 2001; Strindelius et al., 2004). Our results showed that the 
Salmonella-CTB strain produced more IgG1 isotypes indicating Th2-type re-
sponses, while the Salmonella-LTB strain produced more IgG2a isotypes indicat-
ing Th1-type responses. These results are similar to those of other reports sug-
gesting that the Salmonella delivery system induces a predominance of Th1 type 
responses against both passenger and Salmonella antigens (Vindurampulle et al., 
2004). Th1-dominated cell-mediated responses are likely to be more important for 
clearing P-fimbriated APEC, believed to survive and multiply within macrophages 
(Wigley et al., 2005; Chappell et al., 2009). Thus, these results indicated that the 
Salmonella-LTB strain may be a more effective adjuvant against APEC, which 
survives inside macrophages (Vindurampulle et al., 2004; Bastiani et al., 2005). 
A previous study addressed potential synergy between different adjuvants 
(McCluskie and Davis, 1998). Our present data, however, showed that no syner-
gistic effect was observed after administration of the combination of LTB and 
CTB. PapA-specific sIgA responses in the group immunised with both CTB and 
LTB were lower than those in the individual CTB or LTB groups. The principal 
receptor for both CTB and LTB is GM1-ganglioside, a glycosphingolipid found 
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ubiquitously on the surface of mammalian cells (Freytag and Clements, 2005). 
Thus, further studies could elucidate whether CTB and LTB would compete for 
this receptor, causing decreased immune response. In the light of multiple alter-
native virulence mechanisms mediating the pathogenicity of APEC, investiga-
tions are also needed for inclusion of further virulence antigens into the recombi-
nant live vaccine candidate described in this study. 
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